Literature DB >> 9852076

Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A.

X Deng1, T Ito, B Carr, M Mumby, W S May.   

Abstract

Interleukin 3 (IL-3) stimulates the net growth of murine factor-dependent NSF/N1.H7 and FDC-P1/ER myeloid cells by stimulating proliferation and suppressing apoptosis. Recently, we discovered that Bcl2 is phosphorylated at an evolutionarily conserved serine residue (Ser70) after treatment with the survival agonists IL-3 or bryostatin 1, a potent activator of protein kinase (Ito, T., Deng, X., Carr, B., and May, W. S. (1997) J. Biol. Chem. 272, 11671-11673). In addition, an intact Ser70 was found to be required for Bcl2's ability to suppress apoptosis after IL-3 withdrawal or toxic chemotherapy. We now show that phosphorylation of Bcl2 occurs rapidly after the addition of agonist to IL-3-deprived cells and can be reversed by the action of an okadaic acid (OA)-sensitive phosphatase. A role for protein phosphatase (PP) 2A as the Bcl2 regulatory phosphatase is supported by several observations: 1) dephosphorylation of Bcl2 is blocked by OA, a potent PP1 and PP2A inhibitor; 2) intracellular PP2A, but not PP1, co-localizes with Bcl2; 3) the purified PP2Ac catalytic subunit directly dephosphorylates Bcl2 in vitro in an OA-sensitive manner; 4) the purified PP2Ac catalytic subunit preferentially dephosphorylates Bcl2 in vitro compared with PP1 and PP2B; 5) reciprocal immunoprecipitation studies indicate a direct interaction between PP2A and hemagglutinin (HA)-Bcl2; and 6) treatment of factor-deprived cells with bryostatin 1 dramatically increases the association between PP2A and Bcl2. Increased association between Bcl2 and PP2A occurs 15 min after agonist stimulation when Bcl2 phosphorylation has peaked and immediately before dephosphorylation. An agonist-induced increased association of PP2A and Bcl2 fails to occur in cells expressing the inactive, phosphorylation-negative S70A Bcl2 mutant, which indicates that an intact Ser70 site is necessary and sufficient for the interaction to occur. Functional phosphorylation of Bcl2 at Ser70 is proposed to be a dynamic process regulated by the sequential action of an agonist-activated Bcl2 kinase and PP2A.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9852076     DOI: 10.1074/jbc.273.51.34157

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits.

Authors:  Adam M Silverstein; Christina A Barrow; Anthony J Davis; Marc C Mumby
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

2.  Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein.

Authors:  S Tsuzuki; M Towatari; H Saito; T Enver
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Bcl2's flexible loop domain regulates p53 binding and survival.

Authors:  Xingming Deng; Fengqin Gao; Tammy Flagg; Jessica Anderson; W Stratford May
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

4.  Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding.

Authors:  Xingming Deng; Fengqin Gao; W Stratford May
Journal:  Blood       Date:  2008-10-09       Impact factor: 22.113

5.  c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis.

Authors:  Xuefang Cao; Richard L Bennett; W Stratford May
Journal:  J Biol Chem       Date:  2008-03-28       Impact factor: 5.157

6.  Protein phosphatase 2A catalytic subunit α (PP2Acα) maintains survival of committed erythroid cells in fetal liver erythropoiesis through the STAT5 pathway.

Authors:  Weiqian Chen; Pengyu Gu; Xuan Jiang; Hai-Bin Ruan; Chaojun Li; Xiang Gao
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

7.  Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.

Authors:  Peter P Ruvolo; Liran Zhou; Julie C Watt; Vivian R Ruvolo; Jared K Burks; Tilahun Jiffar; Steven Kornblau; Marina Konopleva; Michael Andreeff
Journal:  J Cell Biochem       Date:  2011-06       Impact factor: 4.429

8.  Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

Authors:  B Douglas Smith; Richard J Jones; Eunpi Cho; Jeanne Kowalski; Judith E Karp; Steven D Gore; Milada Vala; Brooke Meade; Sharyn D Baker; Ming Zhao; Steven Piantadosi; Zhe Zhang; Gideon Blumenthal; Erica D Warlick; Robert A Brodsky; Anthony Murgo; Michelle A Rudek; William H Matsui
Journal:  Leuk Res       Date:  2010-07-03       Impact factor: 3.156

9.  Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.

Authors:  B Wang; M Xie; R Li; T K Owonikoko; S S Ramalingam; F R Khuri; W J Curran; Y Wang; X Deng
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

10.  Protein phosphatase 4 regulates apoptosis in leukemic and primary human T-cells.

Authors:  Mirna Mourtada-Maarabouni; Gwyn T Williams
Journal:  Leuk Res       Date:  2009-06-18       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.